文献速递血液透析通路

动静脉透析移植物经皮血栓清除术的围术期与远期结局

Perioperative and long-term outcomes after percutaneous thrombectomy of arteriovenous dialysis access grafts.
PubMed 文献 · J Vasc Surg · 2020-04-11

该回顾性分析纳入2015至2017年77例患者86条动静脉透析移植物(AVG)共218次经皮血栓清除术,评估围术期结局、远期通畅率与再干预情况。术后30天内24.8%移植物需重复经皮血栓清除、14.3%需置入隧道透析导管;1年与3年免于反复血栓形成率分别为37%和18%,免于新透析通路置入率分别为66%和51%,3年总生存率82%。

要点

  • AVG经皮血栓清除术安全,未发生静脉血栓栓塞、心脑血管或临床显著肺栓塞并发症。
  • 术后1年和3年免于反复血栓形成率仅37%和18%,需重视早期再干预。
  • 该微创方法可为透析通路选择有限的高危患者延长AVG使用时间。

核心结论

  • AVG经皮血栓清除术安全,通畅率可接受,可为透析通路选择有限的高危患者延长AVG使用。

研究设计与样本

  • 回顾性分析2015至2017年全部AVG经皮血栓清除术,共77例患者86条AVG、218次手术。
  • 手术多采用机械血栓清除,偶用组织型纤溶酶原激活剂化学溶栓,并用导丝球囊取栓处理流入道,必要时行流入道与流出道辅助介入。

主要发现

  • 患者平均年龄61.1±13.0岁,53.2%为男性,68.8%为黑人。
  • 血栓清除时73.8%行静脉流出道介入,4.5%行动脉流入道介入。
  • 30天内24.8%的去栓移植物需重复经皮血栓清除,14.3%需置入隧道透析导管,4%出现轻度穿刺点或移植物感染,1例因上肢缺血行外科动脉取栓。
  • 未发生静脉血栓栓塞、心肺或脑血管并发症,也无临床显著肺栓塞。
  • 术后1年和3年免于反复血栓形成率分别为37%和18%,免于新透析通路置入率分别为66%和51%,3年总生存率82%。

临床怎么用

  • 对AVG血栓闭塞可优先考虑经皮血栓清除术,围术期需警惕约四分之一病例需重复去栓。
  • 术后应密切随访移植物功能,因远期免于反复血栓形成率偏低,需提前规划再次干预或新通路。
  • 对透析通路选择有限的高危患者,该方法可作为延长AVG使用时间的微创选择。

局限性

  • 为单中心回顾性分析,样本为77例患者86条AVG,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Maintenance of functional arteriovenous grafts (AVGs) for dialysis is difficult secondary to low primary patency, need for reinterventions, and limited alternative dialysis access options. We assessed our experience with percutaneous thrombectomy for treatment of occluded AVGs. METHODS: We performed a retrospective analysis of all percutaneous thrombectomies for AVGs from 2015 to 2017. These were generally performed using mechanical thrombectomy and occasional chemical tissue plasminogen activator thrombolysis, over-the-wire balloon embolectomy for inflow, and adjunctive inflow and outflow interventions as necessary. Perioperative outcomes, long-term patency, reinterventions, and need for new permanent access placement were analyzed. RESULTS: There were 218 percutaneous thrombectomies performed on 86 AVGs in 77 patients. Approximately half (53.2%) of the patients were male and 68.8% were black. Mean age was 61.1 ± 13.0 years. At the time of thrombectomy, 73.8% underwent venous outflow interventions and 4.5% underwent arterial inflow interventions. Within 30 days, 24.8% of declotted grafts underwent repeated percutaneous thrombectomy, 14.3% required tunneled dialysis catheter placement, 4% developed minor access site or graft infections, and one patient underwent surgical arterial thrombectomy for arm ischemia. There were no venous thromboembolic, cardiopulmonary, or cerebrovascular complications or clinically significant pulmonary embolism. At 1 year and 3 years after percutaneous thrombectomy, freedom from repeated thrombosis was 37% and 18%, respectively, and freedom from new dialysis access placement was 66% and 51%, respectively. Overall patient survival was 82% at 3 years. CONCLUSIONS: Percutaneous thrombectomy of AVGs is safe and is associated with acceptable patency rates. This minimally invasive method extends AVG use for these high-risk patients with limited dialysis access options.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Arinze N, Ryan T, Pillai R, et al. Perioperative and long-term outcomes after percutaneous thrombectomy of arteriovenous dialysis access grafts. J Vasc Surg. 2020. PMID: 32289439. doi:10.1016/j.jvs.2020.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。